Eculizumab is a humanized IgG2–G4-kappa antibody that targets complement 5 (C5), previously established as therapy for disorders such as hemolytic uremic syndrome and paroxysmal nocturnal hemoglobinuria [32]. Here, C5 is linked to hemolytic-uremic syndrome.